AnaptysBio, Inc. (ANAB)
ANAB Stock Price Chart
Explore AnaptysBio, Inc. interactive price chart. Choose custom timeframes to analyze ANAB price movements and trends.
ANAB Company Profile
Discover essential business fundamentals and corporate details for AnaptysBio, Inc. (ANAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
26 Jan 2017
Employees
104.00
Website
https://www.anaptysbio.comCEO
Daniel Faga
Description
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB Financial Timeline
Browse a chronological timeline of AnaptysBio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is -$0.13, while revenue estimate is $17.33m.
Earnings released on 12 May 2026
EPS came in at -$1.84 falling short of the estimated -$0.32 by -475.00%, while revenue for the quarter reached $25.56m , beating expectations by +35.48%.
Stock split effective on 20 Apr 2026
Shares were split 3 : 2 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 3 Mar 2026
EPS came in at $1.58 surpassing the estimated $0.89 by +77.53%, while revenue for the quarter reached $108.25m , beating expectations by +24.37%.
Earnings released on 4 Nov 2025
EPS came in at $0.52 surpassing the estimated -$1.06 by +149.06%, while revenue for the quarter reached $76.32m , beating expectations by +248.19%.
Earnings released on 7 Aug 2025
EPS came in at -$1.34 surpassing the estimated -$1.50 by +10.67%, while revenue for the quarter reached $22.26m , beating expectations by +90.54%.
Earnings released on 5 May 2025
EPS came in at -$1.28 surpassing the estimated -$1.30 by +1.54%, while revenue for the quarter reached $27.77m , beating expectations by +81.82%.
Earnings released on 27 Feb 2025
EPS came in at -$0.72 surpassing the estimated -$1.55 by +53.55%, while revenue for the quarter reached $43.11m , beating expectations by +453.91%.
Earnings released on 5 Nov 2024
EPS came in at -$1.14 surpassing the estimated -$1.72 by +33.72%, while revenue for the quarter reached $30.02m , beating expectations by +265.83%.
Earnings released on 5 Aug 2024
EPS came in at -$1.71 falling short of the estimated -$1.20 by -42.50%, while revenue for the quarter reached $10.97m , missing expectations by -51.79%.
Earnings released on 9 May 2024
EPS came in at -$1.64 falling short of the estimated -$1.54 by -6.49%, while revenue for the quarter reached $7.18m , beating expectations by +79.43%.
Earnings released on 12 Mar 2024
EPS came in at -$1.59 surpassing the estimated -$1.60 by +0.67%, while revenue for the quarter reached $9.01m , beating expectations by +137.89%.
Earnings released on 2 Nov 2023
EPS came in at -$1.41 surpassing the estimated -$1.72 by +18.02%, while revenue for the quarter reached $3.32m , beating expectations by +44.98%.
Earnings released on 7 Aug 2023
EPS came in at -$1.50 surpassing the estimated -$1.70 by +11.53%, while revenue for the quarter reached $3.46m , beating expectations by +28.90%.
Earnings released on 11 May 2023
EPS came in at -$1.58 falling short of the estimated -$1.04 by -51.92%, while revenue for the quarter reached $1.37m , missing expectations by -52.56%.
Earnings released on 1 Mar 2023
EPS came in at -$0.93 falling short of the estimated -$0.92 by -1.09%, while revenue for the quarter reached $6.81m , beating expectations by +17.71%.
Earnings released on 8 Nov 2022
EPS came in at -$1.18 falling short of the estimated -$0.47 by -151.06%, while revenue for the quarter reached $1.29m , missing expectations by -90.37%.
Earnings released on 8 Aug 2022
EPS came in at -$1.15 falling short of the estimated -$0.98 by -17.11%, while revenue for the quarter reached $1.22m , missing expectations by -77.04%.
Earnings released on 4 May 2022
EPS came in at -$1.31 falling short of the estimated -$0.99 by -31.67%, while revenue for the quarter reached $970.00k , missing expectations by -80.81%.
Earnings released on 7 Mar 2022
EPS came in at -$1.13 falling short of the estimated $2.28 by -149.56%, while revenue for the quarter reached $1.01m , beating expectations by +3.59%.
Earnings released on 4 Nov 2021
EPS came in at -$0.24 surpassing the estimated -$0.74 by +67.57%, while revenue for the quarter reached $20.89m , beating expectations by +174.87%.
Earnings released on 9 Aug 2021
EPS came in at -$0.02 surpassing the estimated -$0.15 by +86.67%, while revenue for the quarter reached $30.03m , beating expectations by +3.97%.
ANAB Stock Performance
Access detailed ANAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
